A hallmark of Alzheimer's disease (AD) is the aggressive appearance of plaques of amyloid beta (A␤) peptides, which result from the sequential cleavage of amyloid precursor protein (APP) by the ␤-and ␥-secretases. A␤ production is evaded by alternate cleavage of APP by the ␣-and ␥-secretases. Carnosic acid (CA) has been proven to activate the transcription factor Nrf2, a main regulator of the antioxidant response. We investigated the effects of CA on the production of A␤ 1-42 peptide (A␤42) and on the expressions of the related genes in SH-SY5Y human neuroblastoma cells. The treatment of cells with CA suppressed A␤42 secretion (61% suppression at 30 M). CA treatment enhanced the mRNA expressions of an ␣-secretase TACE (tumor necrosis factor-˛-converting enzyme, also called a disintegrin and metalloproteinase-17, ADAM17) significantly and another ␣-secretase ADAM10 marginally; however, the ␤-secretase BACE1 (ˇ-site APP-cleaving enzyme-1) was not increased by CA. Knockdown of TACE by siRNA reduced soluble-APP␣ secretion enhanced by CA and partially recovered the CA-suppressed A␤42 secretion. These results suggest that CA reduces A␤42 production by activating TACE without promoting BACE1 in human neuroblastoma cells. The use of CA may have a potential in the prevention of A␤-mediated diseases, particularly AD.
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Abbreviations: A␤, amyloid-␤; AD, Alzheimer's disease; ADAM, a disintegrin and metalloproteinase; APP, amyloid precursor protein; BACE1, ␤-site APP-cleaving enzyme-1; BCA, bicinchoninic acid; BSA, bovine serum albumin; CA, carnosic acid; CHAPS, 3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate; CHX, cycloheximide; DMEM, Dulbecco's Modified Eagle's Medium; DMSO, dimethyl sulfoxide; ECE1, endothelin-converting enzyme-1; ELISA, enzyme-linked immumosorbent assay; FBS, fetal bovine serum; HRP, horseradish peroxidase; IDE, insulin-degrading enzyme; MAPK, mitogen-activated protein kinase; MT1-MMP, membrane type-1 matrix metalloprotease; NEP, neprilysin; NF-kappaB, nuclear factor kappa-lightchain-enhancer of activated B cells; NGF, nerve growth factor; Nrf2, nuclear factor-erythroid 2-related factor 2; PBS, phosphate-buffered saline; PI3K, phosphoinositide 3-kinase; PS1, presenilin-1; PVDF, polyvinylidene fluoride; RT-PCR, reverse transcription-polymerase chain reaction; SAPK/JNK, stress-activated protein kinase/c-Jun N-terminal kinase; sAPP␣, soluble APP␣; sAPP␤, soluble APP␤; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; TACE, tumor necrosis factor-␣-converting enzyme.
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